<DOC>
	<DOCNO>NCT00289224</DOCNO>
	<brief_summary>The primary purpose study estimate efficacy two-dose regimen oral kill bivalent cholera vaccine administer individual reside cholera-endemic area India .</brief_summary>
	<brief_title>Randomized Controlled Trial Killed Oral Cholera Vaccine Kolkata</brief_title>
	<detailed_description>Cholera remain serious public health problem worldwide . Provision safe water food , establishment adequate sanitation , implementation personal community hygiene constitute main public health intervention cholera . These measure implement fully near future cholera-endemic area . A safe , effective , affordable vaccine would useful tool cholera prevention control.The World Health Organization recently recommend new generation cholera vaccine consider certain endemic epidemic situation , indicate demonstration project need provide information cost , feasibility , impact use vaccine . Starting mid-1980s , follow technology transfer Prof Jan Holmgren Sweden , Vietnamese scientist National Institute Hygiene Epidemiology ( NIHE ) Hanoi develop produce oral , kill cholera vaccine country 's public health program ( 10 ) . Since licensure oral cholera vaccine Vietnam , 5 million dos administer without report serious adverse event . The vaccine produce accord recommend WHO guideline ( 6 ) NIHE 's newly privatize arm , Company Vaccine Biological Production No . 1 ( VABIOTECH ) Hanoi . Recently vaccine reformulate order comply WHO standard internationalize vaccine . Phase II trial reformulate vaccine perform among 148 adult SonLa , Vietnam ( 18 ) among 100 adult 100 child Kolkata , India . Results trial reveal vaccine safe immunogenic . A double-blind randomised phase III trial reformulate oral kill bivalent cholera vaccine urban slum site Kolkata propose National Institute Cholera Enteric Diseases ( NICED ) collaboration International Vaccine Institute ( IVI ) . The IVI negotiate agreement VABIOTECH Shantha Biotechnics PVT LTD vaccine placebo use trial . VABIOTECH produce bulk oral kill bivalent cholera vaccine quality control condition supervise IVI staff . Shanta purchase bulk vaccine VABIOTECH , fill finish bulk vaccine , obtain regulatory clearance use vaccine phase III trial . Shanta purchase bulk placebo agent use trial IVAC ( also Vietnam ) Shanta fill finish placebo obtain regulatory clearance use placebo phase III trial . Shanta later obtain technology future production oral kill bivalent cholera vaccine . The result trial pave way use vaccine India cholera-endemic area .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Cholera</mesh_term>
	<mesh_term>Vibrio Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All healthy , consent , nonpregnant ( ascertained history ) resident least 1 year age study area individual weak get bed receive vaccine ; pregnant woman ( identify verbal screen ) ; le 1 year age</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bivalent kill whole cell oral cholera vaccine</keyword>
	<keyword>double blind randomize clinical trial</keyword>
</DOC>